| Dr Basil Albert Defranco, DO | |
|
206 E Brown St, East Stroudsburg, PA 18301-3006 | |
| (570) 476-3625 | |
| (570) 476-6761 |
| Full Name | Dr Basil Albert Defranco |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 25 Years |
| Location | 206 E Brown St, East Stroudsburg, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821038415 | NPI | - | NPPES |
| 0019248100001 | Medicaid | PA | |
| DE1427177 | Other | PA | BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD419859 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Medical Center | Reading, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Physician Associates Of Pennsylvania Pc | 5597663252 | 42 |
News Archive
Sosei Group Corporation, announces that results reported today by Novartis from the pivotal Phase III GLOW2 clinical trial show that once-daily NVA237 50 mcg significantly improved lung function in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) relative to placebo, with similar efficacy to open-label tiotropium.
The invasion of cancer cells into the lymph vessels that connect the breast to surrounding lymph nodes is the first step leading to the metastasis, or spread, of cancer throughout the body. Metastasis is the primary cause of breast cancer deaths. Surprisingly little is known about the control of this process and how it might be interrupted to prolong the lives of women with breast cancer.
Too often, it's only after a transplanted organ has sustained serious damage that a biopsy reveals the organ is in rejection. A new screening method using sensor particles and a urine test could catch rejection much earlier, more comprehensively, and without a biopsy needle.
Recent clinical trials have indicated that immune checkpoint blockade (ICB) therapy, which is designed to unleash a patient's immune system to attack cancer, has been revolutionary in its implications for breast cancer treatment, especially for its potential to treat patients with triple negative breast cancer.
› Verified 9 days ago
| Entity Name | Emergency Physician Associates Of Pennsylvania Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619990900 PECOS PAC ID: 5597663252 Enrollment ID: O20040913000755 |
News Archive
Sosei Group Corporation, announces that results reported today by Novartis from the pivotal Phase III GLOW2 clinical trial show that once-daily NVA237 50 mcg significantly improved lung function in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) relative to placebo, with similar efficacy to open-label tiotropium.
The invasion of cancer cells into the lymph vessels that connect the breast to surrounding lymph nodes is the first step leading to the metastasis, or spread, of cancer throughout the body. Metastasis is the primary cause of breast cancer deaths. Surprisingly little is known about the control of this process and how it might be interrupted to prolong the lives of women with breast cancer.
Too often, it's only after a transplanted organ has sustained serious damage that a biopsy reveals the organ is in rejection. A new screening method using sensor particles and a urine test could catch rejection much earlier, more comprehensively, and without a biopsy needle.
Recent clinical trials have indicated that immune checkpoint blockade (ICB) therapy, which is designed to unleash a patient's immune system to attack cancer, has been revolutionary in its implications for breast cancer treatment, especially for its potential to treat patients with triple negative breast cancer.
› Verified 9 days ago
| Entity Name | Emergency Care Services Of Pennsylvania Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114955010 PECOS PAC ID: 1759301799 Enrollment ID: O20051206000046 |
News Archive
Sosei Group Corporation, announces that results reported today by Novartis from the pivotal Phase III GLOW2 clinical trial show that once-daily NVA237 50 mcg significantly improved lung function in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) relative to placebo, with similar efficacy to open-label tiotropium.
The invasion of cancer cells into the lymph vessels that connect the breast to surrounding lymph nodes is the first step leading to the metastasis, or spread, of cancer throughout the body. Metastasis is the primary cause of breast cancer deaths. Surprisingly little is known about the control of this process and how it might be interrupted to prolong the lives of women with breast cancer.
Too often, it's only after a transplanted organ has sustained serious damage that a biopsy reveals the organ is in rejection. A new screening method using sensor particles and a urine test could catch rejection much earlier, more comprehensively, and without a biopsy needle.
Recent clinical trials have indicated that immune checkpoint blockade (ICB) therapy, which is designed to unleash a patient's immune system to attack cancer, has been revolutionary in its implications for breast cancer treatment, especially for its potential to treat patients with triple negative breast cancer.
› Verified 9 days ago
| Entity Name | Pennsylvania Hm Associates, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841637865 PECOS PAC ID: 0547404337 Enrollment ID: O20130917000686 |
News Archive
Sosei Group Corporation, announces that results reported today by Novartis from the pivotal Phase III GLOW2 clinical trial show that once-daily NVA237 50 mcg significantly improved lung function in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) relative to placebo, with similar efficacy to open-label tiotropium.
The invasion of cancer cells into the lymph vessels that connect the breast to surrounding lymph nodes is the first step leading to the metastasis, or spread, of cancer throughout the body. Metastasis is the primary cause of breast cancer deaths. Surprisingly little is known about the control of this process and how it might be interrupted to prolong the lives of women with breast cancer.
Too often, it's only after a transplanted organ has sustained serious damage that a biopsy reveals the organ is in rejection. A new screening method using sensor particles and a urine test could catch rejection much earlier, more comprehensively, and without a biopsy needle.
Recent clinical trials have indicated that immune checkpoint blockade (ICB) therapy, which is designed to unleash a patient's immune system to attack cancer, has been revolutionary in its implications for breast cancer treatment, especially for its potential to treat patients with triple negative breast cancer.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Basil Albert Defranco, DO 1000 River Rd, Suite 100, Conshohocken, PA 19428-2439 Ph: (610) 834-2828 | Dr Basil Albert Defranco, DO 206 E Brown St, East Stroudsburg, PA 18301-3006 Ph: (570) 476-3625 |
News Archive
Sosei Group Corporation, announces that results reported today by Novartis from the pivotal Phase III GLOW2 clinical trial show that once-daily NVA237 50 mcg significantly improved lung function in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) relative to placebo, with similar efficacy to open-label tiotropium.
The invasion of cancer cells into the lymph vessels that connect the breast to surrounding lymph nodes is the first step leading to the metastasis, or spread, of cancer throughout the body. Metastasis is the primary cause of breast cancer deaths. Surprisingly little is known about the control of this process and how it might be interrupted to prolong the lives of women with breast cancer.
Too often, it's only after a transplanted organ has sustained serious damage that a biopsy reveals the organ is in rejection. A new screening method using sensor particles and a urine test could catch rejection much earlier, more comprehensively, and without a biopsy needle.
Recent clinical trials have indicated that immune checkpoint blockade (ICB) therapy, which is designed to unleash a patient's immune system to attack cancer, has been revolutionary in its implications for breast cancer treatment, especially for its potential to treat patients with triple negative breast cancer.
› Verified 9 days ago
Richard Cornish, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 206 E Brown St, Somerset Hospital, East Stroudsburg, PA 18301 Phone: 570-476-3625 | |
Dr. Virginia Ann Gortych-barnes, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 206 E Brown St, East Stroudsburg, PA 18301 Phone: 570-476-3578 | |
Dr. Michael Bulette, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 206 E Brown St, East Stroudsburg, PA 18301 Phone: 570-476-3628 Fax: 570-476-6761 | |
Dr. Christopher Joseph Amrick, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 206 E Brown St, East Stroudsburg, PA 18301 Phone: 570-476-3625 Fax: 570-476-6761 | |
Dr. Richard J Tabor, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 206 E Brown St, East Stroudsburg, PA 18301 Phone: 570-476-3353 Fax: 570-420-2528 | |
Lauren Demers, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 206 E Brown St, East Stroudsburg, PA 18301 Phone: 570-421-4000 |